Strategic Focus and Development Priorities - The company prioritizes clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells [1] - The modified strategy extends the expected cash runway into 2026, with potential for multiple data readouts in 2024 and 2025 [1] - The company will suspend development of SC291 in oncology and SC379 (glial progenitor cell program) while seeking partnerships for these programs [1] - Increased investment in the type 1 diabetes program is planned, utilizing cash savings from the strategic changes [1] Clinical Data and Therapeutic Potential - Early clinical data with the hypoimmune platform (HIP) suggest that HIP-modified cells evade immune detection, indicating potential across multiple therapeutic areas [2] - The company expects to present robust clinical data for type 1 diabetes, SC291 in autoimmune diseases, and SC262 in refractory blood cancers over the next 12 to 18 months [2] - SC291 in B-cell mediated autoimmune diseases shows early clinical data indicating deep B cell depletion, which may drive an immune "reset" and significant clinical benefit in conditions like lupus [3] Program Updates and Expectations - UP421 (HIP-modified primary pancreatic islet cells) in type 1 diabetes: An investigator-sponsored trial is active, with proof of concept data expected in 2024 and/or 2025 [3] - SC291 (HIP-modified CD19-directed allogeneic CAR T) in autoimmune diseases: Enrollment continues in the Phase 1 GLEAM trial, with clinical data expected in 2024 and/or 2025 [4] - SC262 (HIP-modified CD22-directed allogeneic CAR T) in oncology: Enrollment continues in the Phase 1 VIVID study, with data expected in 2025 [4] - SC451 (HIP-modified stem cell-derived pancreatic islet cells) in type 1 diabetes: Preclinical development continues [5] - SG299 (in vivo CAR T with CD8-targeted fusogen delivery of a CD19-directed CAR): Preclinical development continues, with potential in both autoimmune diseases and oncology [5] Pipeline Adjustments and Partnerships - SC291 in oncology: Enrollment and further internal investment in the Phase 1 ARDENT trial are halted due to alternative opportunities and increased competition in blood cancers The company is seeking a licensing partner [6] - SC379 (stem-cell derived glial progenitor cells) in CNS diseases: The company is actively seeking a partner or opportunity to spin out this program into a new company [7] Financial and Operational Impact - The modified strategy extends the expected cash runway into 2026, though 2024 operating cash burn may exceed prior guidance of less than $200 million due to ongoing activities and workforce reductions [2]

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Sana's website at ...

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update. Sana will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 11:30 a.m. ET on Wednesday, September 4, 2024. Sana will present at the 2024 Wells Fargo Healthcare ...

Core Insights - Sana Biotechnology, Inc. has appointed Dr. Dhaval Patel as Executive Vice President and Chief Scientific Officer, bringing extensive experience in research and drug development [1][2] - Dr. Patel has a proven track record, having contributed to the advancement of 10 FDA-approved treatments and has expertise in immunology and autoimmune diseases, which aligns with Sana's clinical pipeline focus [2][3] - The company is currently conducting four clinical trials across seven indications, including B-cell mediated autoimmune diseases and type 1 diabetes, indicating a strong commitment to innovative therapies [3] Company Overview - Sana Biotechnology is dedicated to creating engineered cells as medicines, aiming to repair and control genes and replace missing or damaged cells [4] - The company operates in multiple locations including Seattle, WA, Cambridge, MA, South San Francisco, CA, Bothell, WA, and Rochester, NY [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39941 Sana Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-1381173 (State or other jurisdi ...

Exhibit 99.1 Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Recent Corporate Highlights Advancing four clinical programs across seven indications, including an allogeneic CAR T program targeting CD19+ cancers, an allogeneic CAR T program for B-cell mediated autoimmune diseases, an allogeneic CAR T program targeting CD22+ canc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39941 Sana Biotechnology, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 83-1381173 | | --- | --- | | (Stat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39941 Sana Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-1381173 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 188 East Blaine Street, Suite 400 For the quarterly period ende ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39941 Sana Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-1381173 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39941 Sana Biotechnology, Inc. Indicate by check mark whether the registrant has submitted electronically every Interactive Data ...